- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01603043
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
December 3, 2013 updated by: Alcon Research
A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL-78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Participants meeting inclusion/exclusion criteria were randomized in a 2:1 ratio to receive AL-78898A or a sham injection.
The study eye was assessed before and after each injection to ensure that the injection procedure and/or study medication had not endangered the health of the eye.
The Investigator determined each month whether the patient was eligible to receive the next injection.
The study was terminated due to a high likelihood that continued enrollment would reach the predefined study stopping criteria based upon the number of patients with drug deposit formation, which made an assessment of efficacy futile.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to provide informed consent and comply with the protocol.
- Diagnosis of bilateral geographic atrophy (GA) of the macula secondary to age-related macular degeneration, confirmed within 14 days prior to randomization.
- Study eye: Maximum best-corrected visual acuity (BCVA) of 55 letters (20/80 Snellen equivalent) and a minimum BCVA of 20 letters (20/400 Snellen equivalent) at screening
- BCVA of 20 letters (20/400 Snellen equivalent) or better in the non treated eye at screening without conditions other than AMD that, in the opinion of the investigator, could cause a rapid loss of vision.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Any history or current evidence of exudative ("wet") AMD in study eye.
- Retinal disease other than AMD in the study eye.
- Any ophthalmologic condition in study eye that reduces the clarity of the media and that, in the opinion of the Investigator interferes with ophthalmologic examination, such as advanced cataract or corneal abnormalities.
- Any ophthalmologic condition in study eye that prevents adequate imaging of the retina judged by the site or reading center.
- A history or current medical diagnosis of glaucoma or ocular hypertension in study eye.
- Any ophthalmic condition in study eye that may require surgery during the study period.
- Current ocular or periocular infection in the study eye.
- History of any disease or current use of medication expected to cause systemic or ocular immunosuppression, such as RESTASIS®.
- History of uveitis or endophthalmitis in the study eye.
- History of intraocular surgery (including cataract surgery) in the study eye within 90 days prior to dosing.
- History of intravitreal or periocular injection in the study eye at anytime.
- Participation in another interventional clinical study, or use of any experimental treatment for AMD or any other investigational new drug within 6 weeks or during active period of drug (whichever is longer) prior to the start of study treatment.
- History of any medical or psychiatric condition, or substance abuse, that in the Investigator's opinion is likely to interfere with the patient's participation in the study, or likely to cause serious adverse events during the study.
- Women of child bearing potential UNLESS they are using a highly effective method of birth control.
- Known or suspected allergy or hypersensitivity to fluorescein or other injectables.
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AL-78898A
1 intravitreal injection per month for up to 12 months
|
0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
|
SHAM_COMPARATOR: Sham Injection
1 mock injection per month for 12 months
|
Mock injection administered as an empty hub without needle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in GA Lesion Size at Month 12 as Assessed With FAF Imaging
Time Frame: Day 0 (injection visit), Month 12
|
Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.
|
Day 0 (injection visit), Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yearly GA Lesion Size Growth Rate
Time Frame: Baseline (Day 0), up to Month 12
|
Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.
|
Baseline (Day 0), up to Month 12
|
Mean Change From Baseline in BCVA at Month 12
Time Frame: Baseline (Day 0), Month 12
|
Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.
|
Baseline (Day 0), Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mehdi Hosseini, MD, Alcon Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (ACTUAL)
November 1, 2012
Study Completion (ACTUAL)
November 1, 2012
Study Registration Dates
First Submitted
May 18, 2012
First Submitted That Met QC Criteria
May 21, 2012
First Posted (ESTIMATE)
May 22, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
January 20, 2014
Last Update Submitted That Met QC Criteria
December 3, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-12-020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Geographic Atrophy
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States
-
GlaxoSmithKlineCompletedAtrophy, GeographicUnited States, Canada
-
GlaxoSmithKlineQuintiles, Inc.Completed
-
Carl Zeiss Meditec, Inc.DataMed Devices Inc.CompletedAdvanced Dry AMD With Geographic AtrophyUnited States
-
Alkeus Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy | Age Related Macular Degeneration | AMD | Atrophy, GeographicUnited States
-
Apellis Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy Secondary to Age-related Macular DegenerationUnited States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
-
IVERIC bio, Inc.Active, not recruitingMacular Degeneration | Geographic AtrophyUnited States, Latvia, France, Germany, Spain, Hungary, Canada, Israel, Argentina, Czechia, Colombia, Croatia, Italy
-
Boehringer IngelheimCompletedGeographic AtrophyUnited States
-
Genentech, Inc.Completed
-
Apellis Pharmaceuticals, Inc.CompletedGeographic AtrophyUnited States, Australia, New Zealand
Clinical Trials on Al-78898A
-
Alcon ResearchCompletedExudative Age-Related Macular DegenerationUnited States
-
Alcon ResearchWithdrawn
-
Alios Biopharma Inc.Completed
-
Hospital General Universitario ElcheUnknown
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
Riphah International UniversityCompletedStuttering, AdultPakistan
-
Common SenseCompletedAmniotic ProblemsUnited States